2949-8201

ESMO Real World Data and Digital Oncology

Elsevier

View prefix report (10.1016)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 591 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact591 DOIs
2

Attach ORCID iDs across 443 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact443 DOIs
3

Deposit reference lists for 396 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact396 DOIs

DOIs for this ISSN

Showing the top 5 of 591 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 ESMO Guidance for Reporting Oncology real-World evidence (GR… (10.1016/j.esmorw.2023.10.001)
Abstract ORCID
60.21 15
2 Impact of artificial intelligence in transforming the doctor… (10.1016/j.esmorw.2024.100026)
Abstract ORCID
57.31 13
3 The 1 million words pathology report or the challenge of a r… (10.1016/j.esmorw.2024.100044)
Abstract ORCID
45.15 7
4 Oncology education in the age of artificial intelligence (10.1016/j.esmorw.2024.100079)
Abstract ORCID
45.15 7
5 Real-world outcomes of treatment strategy between first-line… (10.1016/j.esmorw.2024.100058)
Abstract ORCID
42.25 6
6 Real-world radiology data for artificial intelligence-driven… (10.1016/j.esmorw.2025.100120)
Abstract ORCID
42.25 6
7 Bridging communication gaps: the role of voice-enabled AI in… (10.1016/j.esmorw.2025.100138)
Abstract ORCID
42.25 6
8 Clinical trial and real-world evidence of circulating tumor… (10.1016/j.esmorw.2024.100076)
Abstract ORCID
38.91 5
9 Digital twins: a new paradigm in oncology in the era of big… (10.1016/j.esmorw.2024.100056)
Abstract
38.29 33
10 Safety and efficacy of encorafenib–cetuximab combination in… (10.1016/j.esmorw.2024.100055)
Abstract ORCID
34.95 4
11 Machine learning for prediction of 30-day mortality in patie… (10.1016/j.esmorw.2025.100146)
Abstract ORCID
34.95 4
12 Advancing breast cancer research through real-world data fro… (10.1016/j.esmorw.2025.100159)
Abstract ORCID
34.95 4
13 Superhuman performance on urology board questions using an e… (10.1016/j.esmorw.2024.100078)
Abstract
33.56 21
14 Implementing digital patient-reported outcomes in routine ca… (10.1016/j.esmorw.2024.100088)
Abstract
31.38 17
15 Real-world treatment patterns and challenges of patients wit… (10.1016/j.esmorw.2024.100060)
Abstract ORCID
30.10 3
16 Incidence, risk factors, and clinical implications of enfort… (10.1016/j.esmorw.2024.100094)
Abstract ORCID
30.10 3
17 Establishment of the Campania Oncology Network (Rete Oncolog… (10.1016/j.esmorw.2025.100126)
Abstract ORCID
30.10 3
18 Time to adjuvant chemotherapy and overall survival in advanc… (10.1016/j.esmorw.2025.100143)
Abstract ORCID
30.10 3
19 Benchmarking cancer outcomes in Europe: a scoping review of… (10.1016/j.esmorw.2025.100176)
Abstract ORCID
30.10 3
20 Real-world safety and effectiveness of neoadjuvant chemother… (10.1016/j.esmorw.2024.100061)
Abstract
27.85 12
21 READY: REAl-world Data from an Italian compassionate use pro… (10.1016/j.esmorw.2024.100068)
Abstract
26.98 11
22 Artificial intelligence for cancer screening and surveillanc… (10.1016/j.esmorw.2024.100046)
Abstract
26.03 10
23 Clinical decision impact of HER2DX, an algorithm-powered gen… (10.1016/j.esmorw.2025.100123)
Abstract
25.00 9
24 EBANO study: real-world data from patients with locally adva… (10.1016/j.esmorw.2024.100063)
Abstract ORCID
23.86 2
25 Real-world occurrence, therapy, and outcome of patients with… (10.1016/j.esmorw.2024.100075)
Abstract ORCID
23.86 2
26 Neutrophil to lymphocyte ratio and tumour burden for treatme… (10.1016/j.esmorw.2024.100106)
Abstract ORCID
23.86 2
27 Perspectives, willingness, and current use of mobile health… (10.1016/j.esmorw.2025.100115)
Abstract ORCID
23.86 2
28 Establishing standards: harmonising coding principles for a… (10.1016/j.esmorw.2025.100179)
Abstract ORCID
23.86 2
29 Clinical evaluation of an automated pan-organ combined PD-L1… (10.1016/j.esmorw.2025.100181)
Abstract ORCID
23.86 2
30 36P Interpretable histomorphological subtypes linked to ICI… (10.1016/j.esmorw.2025.100235)
Abstract References ORCID
22.58 1
31 60eP Machine learning-guided integration of transcriptomic d… (10.1016/j.esmorw.2025.100259)
Abstract References ORCID
22.58 1
32 266P Comparative analysis of machine learning algorithms for… (10.1016/j.esmorw.2025.100462)
Abstract References ORCID
22.58 1
33 385P VacDesignR®: A computational tool to optimize viral-bas… (10.1016/j.esmorw.2025.100581)
Abstract References ORCID
22.58 1
34 413P AI-driven privacy-preserving synthetic data generation… (10.1016/j.esmorw.2025.100609)
Abstract References ORCID
22.58 1
35 Relationship of tumor fraction in circulating tumor DNA with… (10.1016/j.esmorw.2023.100004)
Abstract
21.13 6
36 Real-world patterns of treatment and response in metastatic… (10.1016/j.esmorw.2024.100027)
Abstract
21.13 6
37 Real-world safety and effectiveness data of trastuzumab deru… (10.1016/j.esmorw.2024.100095)
Abstract
21.13 6
38 Cardiovascular toxicities in cancer patients treated with im… (10.1016/j.esmorw.2024.100111)
Abstract
21.13 6
39 Real-world evidence reported for clinical efficacy evaluatio… (10.1016/j.esmorw.2024.100039)
Abstract
19.45 5
40 Human-centered AI as a framework guiding the development of… (10.1016/j.esmorw.2024.100077)
Abstract
19.45 5
41 Cancer prevalence and care disparities among individuals wit… (10.1016/j.esmorw.2025.100160)
Abstract
19.45 5
42 UK multicentre real-world data of the use of cyclin-dependen… (10.1016/j.esmorw.2024.100064)
Abstract
17.47 4
43 Transforming breast cancer management with real-world data a… (10.1016/j.esmorw.2024.100067)
Abstract
17.47 4
44 Concordance between patient-reported outcomes and CTCAE clin… (10.1016/j.esmorw.2025.100127)
Abstract
17.47 4
45 Exploring the utility and limitations of ChatGPT in scientif… (10.1016/j.esmorw.2023.09.001)
Abstract
15.05 3
46 DIGICORE, an international research consortium, is building… (10.1016/j.esmorw.2024.100023)
Abstract ORCID
15.05 1
47 Real-world survival of patients treated with taxane therapy… (10.1016/j.esmorw.2024.100024)
Abstract
15.05 3
48 Evaluating GPT-4 as an academic support tool for clinicians:… (10.1016/j.esmorw.2024.100042)
Abstract
15.05 3
49 Clinical impact for advanced non-small-cell lung cancer pati… (10.1016/j.esmorw.2024.100057)
Abstract
15.05 3
50 Using real world data to bridge the evidence gap left by pro… (10.1016/j.esmorw.2024.100073)
Abstract
15.05 3